| Literature DB >> 34902832 |
Apar Kishor P Ganti1, Billy W Loo2, Michael Bassetti3, Collin Blakely4, Anne Chiang5, Thomas A D'Amico6, Christopher D'Avella7, Afshin Dowlati8, Robert J Downey9, Martin Edelman10, Charles Florsheim11, Kathryn A Gold12, Jonathan W Goldman13, John C Grecula14, Christine Hann15, Wade Iams16, Puneeth Iyengar17, Karen Kelly18, Maya Khalil19, Marianna Koczywas20, Robert E Merritt14, Nisha Mohindra21, Julian Molina22, Cesar Moran23, Saraswati Pokharel24, Sonam Puri25, Angel Qin26, Chad Rusthoven27, Jacob Sands28, Rafael Santana-Davila29, Michael Shafique30, Saiama N Waqar31, Kristina M Gregory32, Miranda Hughes32.
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.Entities:
Mesh：
Year: 2021 PMID： 34902832 DOI： 10.6004/jnccn.2021.0058
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908